Plus Therapeutics, Inc. (PSTV) Earnings History
Net Loss28 years of earnings data (1998–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Plus Therapeutics, Inc. (PSTV) Earnings Overview
As of June 23, 2026, Plus Therapeutics, Inc. (PSTV) reported trailing twelve-month net income of -$12M, reflecting +87.7% year-over-year growth. The company earned $-1.80 per diluted share over the past four quarters, with a net profit margin of -429.4%.
Looking at the long-term picture, PSTV's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 1998.
Plus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NRXP (-$25M net income, -2336.5% margin), AGEN ($65M net income, 0.1% margin), CLDX (-$284M net income, -17253.3% margin), PSTV has outperformed on profitability metrics. Compare PSTV vs NRXP →
PSTV Earnings vs Peers
Earnings metrics vs comparable public companies
PSTV Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$22M | -72.5% | -$15M | $-7.19 | -429.4% | -293.5% |
| 2024 | -$13M | +2.5% | -$15M | $-58.50 | -222.8% | -252.3% |
| 2023 | -$13M | +34.3% | -$13M | $-106000.00 | -271.0% | -271.1% |
| 2022 | -$20M | -51.3% | -$20M | $-288750.00 | -9051.3% | -8800.0% |
| 2021 | -$13M | -62.6% | -$12M | $-444500.00 | - | - |
| 2020 | -$8M | +24.3% | -$10M | $-697500.00 | -2719.8% | -3163.0% |
| 2019 | -$11M | +13.8% | -$4M | $-999999.00 | -155.6% | -52.3% |
| 2018 | -$13M | +44.3% | -$9M | $-999999.00 | -423.5% | -293.7% |
| 2017 | -$23M | -2.9% | -$21M | $-999999.00 | -353.9% | -322.6% |
| 2016 | -$22M | -17.6% | -$20M | $-999999.00 | -193.7% | -173.2% |
| 2015 | -$19M | +49.8% | -$15M | $-999999.00 | -160.8% | -131.1% |
| 2014 | -$37M | -42.8% | -$32M | $-999999.00 | -491.8% | -426.9% |
| 2013 | -$26M | +18.9% | -$31M | $-999999.00 | -214.6% | -251.5% |
| 2012 | -$32M | +0.5% | -$28M | $-999999.00 | -222.6% | -195.1% |
| 2011 | -$32M | -18.0% | -$33M | $-999999.00 | -324.6% | -330.5% |
| 2010 | -$27M | -18.4% | -$27M | $-999999.00 | -258.7% | -250.1% |
| 2009 | -$23M | +22.7% | -$22M | $-999999.00 | -157.6% | -146.3% |
| 2008 | -$30M | -4.8% | -$30M | $-999999.00 | -438.3% | -434.3% |
| 2007 | -$29M | -12.7% | -$31M | $-999999.00 | -474.0% | -518.3% |
| 2006 | -$25M | +4.1% | -$26M | $-999999.00 | -321.0% | -326.2% |
| 2005 | -$27M | -1169.8% | -$28M | $-999999.00 | -441.9% | -466.3% |
| 2004 | -$2M | +77.5% | -$16M | $-999999.00 | -30.7% | -235.6% |
| 2003 | -$9M | +28.6% | -$10M | $-999999.00 | -65.9% | -68.6% |
| 2002 | -$13M | -16.0% | -$12M | $-999999.00 | -141.9% | -125.5% |
| 2001 | -$11M | -29.6% | -$11M | $-999999.00 | -198.4% | -202.4% |
| 2000 | -$9M | -89.1% | -$10M | $-999999.00 | -138.3% | -153.7% |
| 1999 | -$5M | -118.7% | -$4M | $-999999.00 | -302.1% | -295.8% |
| 1998 | -$2M | - | -$2M | $-999999.00 | - | - |
Download Data
Export PSTV earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PSTV — Frequently Asked Questions
Quick answers to the most common questions about buying PSTV stock.
What is PSTV earnings per share (EPS)?
PSTV trailing twelve-month (TTM) diluted EPS is $-1.80, reflecting +87.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is Plus Therapeutics, Inc.'s net income?
Plus Therapeutics, Inc. (PSTV) trailing twelve-month net income is $-12M as of 2025. Earnings grew +87.7% year-over-year.
Is PSTV profitable?
PSTV is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is -429.4%. Investors should monitor for a return to profitability.
What is PSTV's earnings growth rate?
PSTV compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are PSTV's profit margins?
Plus Therapeutics, Inc. net profit margin is -429.4%, operating margin is -293.5%, and gross margin is +91.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -560.2%.
Is PSTV growing earnings?
Yes, PSTV earnings are accelerating — EPS growth of +87.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-12M. Earnings momentum is strengthening.
What was PSTV's best earnings year?
Plus Therapeutics, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 1998. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were PSTV's earnings last quarter?
PSTV's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-1.05. For a full breakdown of all quarters, see the quarterly earnings table on this page.